melagatran has been researched along with Venous Thrombosis in 30 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 28 (93.33) | 29.6817 |
| 2010's | 2 (6.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bergmann, JF; Lloret Linares, C | 1 |
| Fujimoto, T; Hiroe, K; Imaeda, Y; Kawamura, M; Konishi, N; Kubo, K; Shofuda, K | 1 |
| Eriksson, H; Eriksson, UG; Lapidus, L; Larson, G; Olsson, CG; Thuresson, A; Wåhlander, K | 1 |
| Agnelli, G; Cohen, AT; Dahl, OE; Eriksson, BI; Eskilson, C; Frison, L; Mouret, P; Nylander, I; Ogren, M; Rosencher, N | 1 |
| Hamaad, A; Lip, GY; Tayebjee, MH | 1 |
| Eriksson, BI; Eriksson, UG; Frison, L; Gisleskog, PO; Gustafsson, D; Hamrén, B; Karlsson, MO; Mandema, JW; Wählby, U | 1 |
| Börjesson, I; Carlsson, S; Elg, M | 1 |
| Gustafsson, D | 1 |
| Drouet, L | 1 |
| Eichinger, S; Kyrle, PA; Weltermann, A | 1 |
| Agnelli, G; Andersson, M; Cohen, AT; Dahl, OE; Eriksson, BI; Eskilson, C; Freij, A; Kälebo, P; Lassen, MR; Mouret, P; Panfilov, S; Rosencher, N | 1 |
| Evans, HC; Faulds, D; Perry, CM | 1 |
| Al-Mousa, EN; Salam, AM | 1 |
| Weitz, J | 1 |
| Bauersachs, R; Brehme, S; Caspary, L; Creutzig, A; Harenberg, J; Hoffmann, U; Landgraf, H; Schellong, S | 1 |
| Brighton, TA | 1 |
| Cimminiello, C; Planès, A; Samama, MM | 1 |
| Boda, Z | 1 |
| Petersen, P | 1 |
| Eriksson, UG; Hellgren, M; Johansson, S; Wåhlander, K | 1 |
| Carlsson, S; Elg, M | 1 |
| Nielsen, JD | 1 |
| Meyer Samama, M | 1 |
| Brighton, TA; Ho, SJ | 1 |
| Hauel, N; Priepke, H; Ries, UJ; Stassen, JM; Wienen, W | 1 |
| Heinzl, S | 1 |
| Arfwidsson, AC; Bylock, A; Eriksson, BI; Eriksson, UG; Fager, G; Frison, L; Gustafsson, D; Kälebo, P | 1 |
| Fiessinger, JN | 1 |
| Andersson, C; Bylock, A; Eriksson, BI; Frison, L; Gustafsson, D; Larson, G; Lindahl, TL; Wåhlander, K | 1 |
| Ahnfelt, L; Arfwidsson, AC; Björkström, S; Elvander, CS; Eriksson, BI; Eriksson, UG; Folestad, A; Frison, L; Kälebo, P; Ogren, M; Sjöstedt, A | 1 |
15 review(s) available for melagatran and Venous Thrombosis
| Article | Year |
|---|---|
The METHRO trials.
Topics: Azetidines; Benzylamines; Clinical Trials as Topic; Glycine; Humans; Orthopedic Procedures; Prodrugs; Thrombin; Venous Thrombosis | 2003 |
Oral direct thrombin inhibitors in clinical development.
Topics: Anticoagulants; Azetidines; Benzimidazoles; Benzylamines; Dabigatran; Glycine; Hemostasis; Humans; Prodrugs; Pyridines; Stroke; Thrombin; Thrombosis; Venous Thrombosis; Vitamin K | 2003 |
[Treatment and prevention of venous thromboembolic events: present and future antithrombotic agents].
Topics: Administration, Oral; Azetidines; Benzylamines; Clinical Trials as Topic; Coronary Thrombosis; Factor Xa Inhibitors; Fibrinolytic Agents; Fondaparinux; Glycine; Hirudin Therapy; Humans; Orthopedics; Polysaccharides; Prodrugs; Prothrombin; Research; Thrombin; Thromboembolism; Time Factors; Venous Thrombosis | 2003 |
Novel anticoagulants for the prevention and treatment of venous thromboembolism.
Topics: Anticoagulants; Azetidines; Benzylamines; Blood Coagulation Factors; Drugs, Investigational; Fondaparinux; Glycine; Heparin; Heparin, Low-Molecular-Weight; Humans; Polysaccharides; Pulmonary Embolism; Research; Thrombin; Venous Thrombosis; Vitamin K | 2003 |
Ximelagatran/Melagatran: a review of its use in the prevention of venous thromboembolism in orthopaedic surgery.
Topics: Anticoagulants; Azetidines; Benzylamines; Drug Interactions; Drug Therapy, Combination; Enoxaparin; Glycine; Humans; Orthopedic Procedures; Randomized Controlled Trials as Topic; Thrombin; Thromboembolism; Venous Thrombosis; Warfarin | 2004 |
The therapeutic potential of ximelagatran to become the anticoagulant of choice in medicine: a review of recently completed clinical trials.
Topics: Anticoagulants; Atrial Fibrillation; Azetidines; Benzylamines; Clinical Trials as Topic; Coronary Artery Disease; Drug Therapy, Combination; Glycine; Humans; Prodrugs; Stroke; Thrombin; Thromboembolism; Venous Thrombosis | 2004 |
Orally active direct thrombin inhibitors.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Azetidines; Benzylamines; Blood Coagulation; Drug Monitoring; Glycine; Humans; International Normalized Ratio; Postoperative Complications; Prodrugs; Stroke; Thrombin; Thrombosis; Venous Thrombosis; Vitamin K | 2003 |
[Prevention and treatment of deep vein thrombosis with ximelagatran].
Topics: Anticoagulants; Arginine; Azetidines; Benzylamines; Fondaparinux; Glycine; Heparin; Hirudin Therapy; Humans; Pipecolic Acids; Polysaccharides; Prodrugs; Sulfonamides; Thrombin; Venous Thrombosis | 2004 |
The direct thrombin inhibitor melagatran/ximelagatran.
Topics: Anticoagulants; Azetidines; Benzylamines; Blood Coagulation; Glycine; Humans; Myocardial Infarction; Secondary Prevention; Stroke; Thrombin; Treatment Outcome; Venous Thrombosis | 2004 |
[New anticoagulants in clinical practice].
Topics: Anticoagulants; Azetidines; Benzylamines; Fondaparinux; Glycine; Humans; Polysaccharides; Protein C; Pulmonary Embolism; Recombinant Proteins; Venous Thrombosis | 2004 |
Ximelagatran--a promising new drug in thromboembolic disorders.
Topics: Administration, Oral; Anticoagulants; Azetidines; Benzylamines; Glycine; Humans; Prodrugs; Randomized Controlled Trials as Topic; Stroke; Thrombin; Thromboembolism; Venous Thrombosis | 2005 |
[Thromboprophylaxis in hip and knee arthroplasty. Are the new anticoagulants better than those previously used?].
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Azetidines; Benzylamines; Clinical Trials, Phase III as Topic; Fibrinolytic Agents; Fondaparinux; Glycine; Humans; Polysaccharides; Postoperative Complications; Pulmonary Embolism; Thromboembolism; Venous Thrombosis | 2005 |
[The new antithrombotic agents].
Topics: Administration, Oral; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Azetidines; Benzylamines; Clopidogrel; Fibrinolytic Agents; Glycine; Hirudins; Humans; Injections, Subcutaneous; Platelet Aggregation Inhibitors; Polysaccharides; Prodrugs; Randomized Controlled Trials as Topic; Stents; Thrombosis; Ticlopidine; Time Factors; Venous Thrombosis | 2005 |
Ximelagatran: direct thrombin inhibitor.
Topics: Acute Disease; Administration, Oral; Anticoagulants; Atrial Fibrillation; Azetidines; Benzylamines; Heart Diseases; Hemostasis; Humans; Molecular Structure; Orthopedic Procedures; Patient Compliance; Patient Satisfaction; Platelet Aggregation; Prodrugs; Stroke; Syndrome; Thrombin; Thromboembolism; Treatment Outcome; Venous Thrombosis | 2006 |
[Treatment of deep vein thrombosis. Current and future questions].
Topics: Administration, Oral; Anticoagulants; Azetidines; Benzylamines; Glycine; Hemorrhage; Heparin, Low-Molecular-Weight; Humans; Polysaccharides; Recurrence; Risk Factors; Venous Thrombosis | 2001 |
7 trial(s) available for melagatran and Venous Thrombosis
| Article | Year |
|---|---|
Pharmacokinetics, pharmacodynamics and clinical effects of the oral direct thrombin inhibitor ximelagatran in acute treatment of patients with pulmonary embolism and deep vein thrombosis.
Topics: Administration, Oral; Adult; Aged; Azetidines; Benzylamines; Female; Fibrinolytic Agents; Glycine; Humans; Male; Middle Aged; Partial Thromboplastin Time; Pharmacokinetics; Prodrugs; Pulmonary Embolism; Thrombin; Treatment Outcome; Venous Thrombosis | 2002 |
Direct thrombin inhibitor melagatran followed by oral ximelagatran in comparison with enoxaparin for prevention of venous thromboembolism after total hip or knee replacement.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Azetidines; Benzylamines; Cause of Death; Double-Blind Method; Drug Administration Schedule; Enoxaparin; Female; Glycine; Hemorrhage; Humans; Injections, Subcutaneous; Male; Middle Aged; Postoperative Complications; Prodrugs; Prospective Studies; Pulmonary Embolism; Safety; Thrombin; Treatment Outcome; Venous Thrombosis | 2003 |
Pharmacokinetics of melagatran and the effect on ex vivo coagulation time in orthopaedic surgery patients receiving subcutaneous melagatran and oral ximelagatran: a population model analysis.
Topics: Administration, Cutaneous; Administration, Oral; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Azetidines; Benzylamines; Biological Availability; Body Weight; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Glycine; Humans; Metabolic Clearance Rate; Partial Thromboplastin Time; Postoperative Complications; Sweden; Thromboembolism; Venous Thrombosis; Whole Blood Coagulation Time | 2003 |
The direct thrombin inhibitor melagatran followed by oral ximelagatran compared with enoxaparin for the prevention of venous thromboembolism after total hip or knee replacement: the EXPRESS study.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Azetidines; Benzylamines; Double-Blind Method; Enoxaparin; Female; Glycine; Hemorrhage; Humans; Male; Middle Aged; Preoperative Care; Therapeutic Equivalency; Thrombin; Thromboembolism; Venous Thrombosis | 2003 |
A dose-ranging study of the oral direct thrombin inhibitor, ximelagatran, and its subcutaneous form, melagatran, compared with dalteparin in the prophylaxis of thromboembolism after hip or knee replacement: METHRO I. MElagatran for THRombin inhibition in
Topics: Administration, Oral; Adolescent; Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Azetidines; Benzylamines; Dalteparin; Female; Glycine; Humans; Incidence; Injections, Subcutaneous; Male; Middle Aged; Partial Thromboplastin Time; Postoperative Complications; Prodrugs; Safety; Sweden; Thrombin; Thromboembolism; Treatment Outcome; Venous Thrombosis | 2002 |
Factor V Leiden (G1691A) and prothrombin gene G20210A mutations as potential risk factors for venous thromboembolism after total hip or total knee replacement surgery.
Topics: Activated Protein C Resistance; Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Azetidines; Benzylamines; Dalteparin; DNA Mutational Analysis; Double-Blind Method; Europe; Factor V; Female; Genetic Predisposition to Disease; Genotype; Glycine; Humans; Male; Middle Aged; Postoperative Complications; Promoter Regions, Genetic; Prospective Studies; Prothrombin; Pulmonary Embolism; Risk Factors; Thrombophilia; Venous Thrombosis | 2002 |
Prophylaxis of venous thromboembolism with subcutaneous melagatran in total hip or total knee replacement: results from Phase II studies.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Azetidines; Benzylamines; Cyclodextrins; Female; Fibrinolytic Agents; Glycine; Hemorrhage; Humans; Injections, Subcutaneous; Male; Middle Aged; Partial Thromboplastin Time; Phlebography; Thromboembolism; Venous Thrombosis | 2002 |
8 other study(ies) available for melagatran and Venous Thrombosis
| Article | Year |
|---|---|
[Story of a predictable death: the end of vitamin K antagonists?].
Topics: Anticoagulants; Azetidines; Benzylamines; France; Hemorrhage; Humans; Pulmonary Embolism; Thromboembolism; Thrombosis; Venous Thrombosis; Vitamin K | 2010 |
Antithrombotic and anticoagulant profiles of TAK-442, a novel factor Xa inhibitor, in a rabbit model of venous thrombosis.
Topics: Animals; Anticoagulants; Azetidines; Benzylamines; Bleeding Time; Blood Coagulation; Blood Coagulation Tests; Dogs; Factor Xa Inhibitors; Fibrinolytic Agents; Humans; Macaca fascicularis; Male; Mice; Mice, Inbred ICR; Morpholines; Pyrazoles; Pyridones; Pyrimidinones; Rabbits; Rats; Rats, Sprague-Dawley; Rivaroxaban; Sulfones; Thiophenes; Thrombin; Venous Thrombosis | 2010 |
Three vehicle formulations for melagatran, a direct thrombin inhibitor, evaluated in a vena cava thrombosis model in the rat.
Topics: Animals; Antithrombins; Azetidines; Benzylamines; Chemistry, Pharmaceutical; Constriction, Pathologic; Cyclodextrins; Delayed-Action Preparations; Disease Models, Animal; Drug Evaluation, Preclinical; Endothelium, Vascular; Glycine; Injections, Subcutaneous; Male; Partial Thromboplastin Time; Pharmaceutical Vehicles; Poloxamer; Rats; Rats, Sprague-Dawley; Solutions; Sweden; Thrombin Time; Vena Cava, Inferior; Venous Thrombosis | 2003 |
Prevention of venous thromboembolism after orthopedic surgery: the EXPRESS study.
Topics: Anticoagulants; Azetidines; Benzylamines; Clinical Trials as Topic; Dissent and Disputes; Enoxaparin; Glycine; Humans; Orthopedic Procedures; Therapeutic Equivalency; Thromboembolism; Treatment Outcome; Venous Thrombosis | 2004 |
The oral direct thrombin inhibitor, ximelagatran, an alternative for anticoagulant treatment during the puerperium and lactation.
Topics: Administration, Oral; Adult; Anticoagulants; Azetidines; Benzylamines; Breast Feeding; Female; Glycine; Humans; Lactation; Milk, Human; Postpartum Period; Puerperal Disorders; Thrombin; Thromboembolism; Venous Thrombosis | 2005 |
The effects of ximelagatran and warfarin on the prophylaxis of a caval vein thrombosis and bleeding in the anaesthetized rat.
Topics: Animals; Azetidines; Benzylamines; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Glycine; Hemorrhage; Male; Rats; Rats, Sprague-Dawley; Venae Cavae; Venous Thrombosis; Warfarin | 2005 |
Antithrombotic and anticoagulant effects of the direct thrombin inhibitor dabigatran, and its oral prodrug, dabigatran etexilate, in a rabbit model of venous thrombosis.
Topics: Administration, Oral; Animals; Anticoagulants; Azetidines; Benzimidazoles; Benzylamines; Dabigatran; Disease Models, Animal; Dose-Response Relationship, Drug; Fibrinolytic Agents; Heparin; Hirudin Therapy; Injections, Intravenous; Male; Partial Thromboplastin Time; Prodrugs; Pyridines; Rabbits; Venous Thrombosis | 2007 |
[New thrombolytic agents].
Topics: Anticoagulants; Azetidines; Benzylamines; Fibrinolytic Agents; Glycine; Heparin; Humans; Thrombosis; Venous Thrombosis | 2001 |